Handelsinvest Investeringsforvaltning boosted its position in Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) by 100.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 40,000 shares of the company’s stock after acquiring an additional 20,000 shares during the period. Handelsinvest Investeringsforvaltning’s holdings in Biohaven Pharmaceutical were worth $1,669,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Nisa Investment Advisors LLC grew its holdings in Biohaven Pharmaceutical by 511.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock worth $46,000 after acquiring an additional 920 shares during the last quarter. Tower Research Capital LLC TRC bought a new stake in Biohaven Pharmaceutical in the 2nd quarter worth $65,000. Aperio Group LLC purchased a new stake in shares of Biohaven Pharmaceutical in the 2nd quarter worth about $71,000. Glen Harbor Capital Management LLC lifted its position in shares of Biohaven Pharmaceutical by 165.9% in the 2nd quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock worth $76,000 after purchasing an additional 1,088 shares during the period. Finally, Canton Hathaway LLC purchased a new stake in shares of Biohaven Pharmaceutical in the 3rd quarter worth about $83,000. 90.87% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Elyse Stock sold 800 shares of Biohaven Pharmaceutical stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $45.01, for a total transaction of $36,008.00. Following the completion of the transaction, the insider now directly owns 800 shares of the company’s stock, valued at approximately $36,008. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Gregory Bailey purchased 5,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were acquired at an average cost of $37.65 per share, with a total value of $188,250.00. Following the completion of the transaction, the director now owns 2,587,601 shares in the company, valued at $97,423,177.65. The disclosure for this purchase can be found here. Company insiders own 23.90% of the company’s stock.

Several equities research analysts have recently commented on BHVN shares. Cantor Fitzgerald set a $87.00 target price on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Zacks Investment Research cut shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Monday. ValuEngine cut shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Saturday. Goldman Sachs Group set a $89.00 target price on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Finally, Oppenheimer set a $67.00 target price on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, October 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $69.36.

NYSE BHVN traded up $1.04 during trading hours on Tuesday, reaching $46.11. 5,289 shares of the company’s stock traded hands, compared to its average volume of 583,318. Biohaven Pharmaceutical Holding Co Ltd has a 52-week low of $29.17 and a 52-week high of $67.86. The firm has a market cap of $2.35 billion, a PE ratio of -7.46 and a beta of 0.32. The firm has a 50-day simple moving average of $43.52 and a 200 day simple moving average of $48.81.

Biohaven Pharmaceutical (NYSE:BHVN) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($2.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.09) by ($0.26). As a group, research analysts expect that Biohaven Pharmaceutical Holding Co Ltd will post -7.43 earnings per share for the current fiscal year.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Read More: What is channel trading?

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.